The consumer genetic testing company says it can barely keep up with demand from researchers, while patient advocates wonder if customers deserve a cut of the profits. The consumer genetic testing company says it can barely keep up with demand from researchers, while patient advocates wonder if customers deserve a cut of the profits. After decades of inconclusive results, researchers backed by Pfizer and Massachusetts General Hospital revealed that they had identified several genetic markers ass...
The consumer genetic testing company says it can barely keep up with demand from researchers, while patient advocates wonder if customers deserve a cut of the profits. The consumer genetic testing company says it can barely keep up with demand from researchers, while patient advocates wonder if customers deserve a cut of the profits. After decades of inconclusive results, researchers backed by Pfizer and Massachusetts General Hospital revealed that they had identified several genetic markers ass...
Share this Article
Recommended